Abstract: This invention relates to novel water soluble metal working fluid compositions, their use to work metal, a process for working metal using such compositions and the metal worked article of manufacture. More particularly, this invention relates to fluid compositions useful in cutting, grinding, shaping and other metal working operations which require a lubricant. The terms “first Group A” and “second Group B” are used herein to denote different groups and not to indicate any sequence of use or selection as any possible combination or sequence of use of a component(s) is envisioned without limit of any kind. The disclosed fluid compositions are also anticorrosive and environmentally more acceptable than current oil based fluids.
Type:
Grant
Filed:
February 24, 1999
Date of Patent:
March 16, 2004
Assignee:
Solutia, Inc.
Inventors:
Dennis J. Kalota, Yueting Chou, Timothy K. Hirzel, David C. Silverman, Jacob S. Tou, Winsor R. Cho
Abstract: This invention relates to novel compounds of formula I
wherein A, B, D, E, G, J, L, X, V are as defined in the specification, and the compounds are useful in the modulation of endogenous growth hormone levels in a mammal.
Type:
Grant
Filed:
April 17, 2001
Date of Patent:
October 28, 2003
Assignee:
Eli Lilly and Company
Inventors:
Kenneth Lee Hauser, Jeffrey Alan Dodge, Mark Louis Heiman, Scott Alan Jones, Charles Arthur Alt, Henry Uhlman Bryant, James Densmore Copp, William Harlan Gritton, Charles Willis Lugar, III, Brian Stephen Muehl, Alan David Palkowitz, Andrew Michael Ratz, Gary Anthony Rhodes, Roger Lewis Robey, Timothy Alan Shepherd, Kenneth Jeff Thrasher, William George Trankle
Abstract: The present invention is directed to methods for the modulation of cardiac function which comprise the administration of certain compounds, as defined herein, having growth hormone secretagogue activity.
Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
Type:
Grant
Filed:
August 4, 1997
Date of Patent:
December 19, 2000
Assignee:
Abbott Laboratories
Inventors:
Martin Winn, Steven A. Boyd, Charles W. Hutchins, Hwan-Soo Jae, Andrew S. Tasker, Thomas W. von Geldern, Jeffrey A. Kester, Bryan K. Sorensen, Bruce G. Szczepankiewicz, Kenneth J. Henry, Gang Liu, Steven J. Wittenberger, Steven A. King
Abstract: A compound of the formula (I): ##STR1## or a pharmaceutically acceptable salt thereof is disclosed, as well as processes for and intermediates in the preparation thereof, and a method of antagonizing endothelin.
Type:
Grant
Filed:
May 29, 1998
Date of Patent:
September 26, 2000
Assignee:
Abbott Laboratories
Inventors:
Andrew S. Tasker, Martin Winn, Steven A. Boyd, Hwan-Soo Jae, Thomas W. von Geldern, Bryan K. Sorensen, Kenneth J. Henry
Abstract: The present invention relates to novel cinnamide compounds that are useful for treating inflammatory and immune diseases, to pharmaceutical compositions comprising these compounds, and to methods of inhibiting inflammation or suppressing immune response in a mammal.
Type:
Grant
Filed:
December 29, 1998
Date of Patent:
August 29, 2000
Assignee:
Abbott Laboratories
Inventors:
James Link, Gang Liu, Zhonghua Pei, Tom von Geldern, Martin Winn, Zhili Xin
Abstract: This invention provides novel indenone derivatives, their pharmaceutical formulations and their use for the inhibition of leukocyte adherence to cells.
Type:
Grant
Filed:
May 1, 1998
Date of Patent:
January 11, 2000
Assignee:
Eli Lilly and Company
Inventors:
John Michael Morin, Jr., Michael Dean Kinnick, Robert Theodore Vasileff, William Thomas Jackson
Abstract: Continuous format high throughput screening (CF-HTS) using at least one porous matrix allows the pharmaceutical industry to simultaneously screen large numbers of chemical entities for a wide range of biological or biochemical activity. In addition, CF-HTS is useful to perform multi-step assays.
Type:
Grant
Filed:
December 12, 1997
Date of Patent:
November 2, 1999
Assignee:
Abbott Laboratories
Inventors:
Bruce A. Beutel, Mark E. Schurdak, Martin J. Voorbach, David J. Burns, Mary K. Joseph
Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.
Type:
Grant
Filed:
March 20, 1997
Date of Patent:
July 6, 1999
Assignee:
Eli Lilly and Company
Inventors:
Margaret M. Faul, Michael R. Jirousek, John H. McDonald, III, David Neel
Abstract: The instant invention provides a series of naphthyl compounds having an oxygen linker at the 1-position which are useful as selective estrogen receptor modulators.
Type:
Grant
Filed:
September 29, 1997
Date of Patent:
June 29, 1999
Assignee:
Eli Lilly and Company
Inventors:
Kenneth Lee Hauser, Alan David Palkowitz
Abstract: The present invention relates to a process for preparing acrylamides; wherein, a propiolamide is reacted with an activated aromatic ring to yield a wide variety of acrylamides.
Abstract: The invention provides naphthofluorene compounds, intermediates, formulations, processes, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions, including hyperlipidemia, and estrogen-dependent cancer.
Type:
Grant
Filed:
September 22, 1997
Date of Patent:
March 30, 1999
Assignee:
Eli Lilly and Company
Inventors:
Henry Uhlman Bryant, Jeffrey Alan Dodge, Charles Willis Lugar, III
Abstract: The present invention provides a method for synthesizing indolylmaleimides by reacting an activated maleimide preferably with an optionally substituted organometallic-3-indole in the presence of a transition metal catalyst.
Type:
Grant
Filed:
December 19, 1997
Date of Patent:
January 12, 1999
Assignee:
Eli Lilly and Company
Inventors:
Margaret M. Faul, Michael R. Jirousek, John H. McDonald, III, David Andrew Neel
Abstract: The invention provides benzo?b!indenothiophene compounds of formula I ##STR1## wherein, R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6, are as defined in the specification, intermediates, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, cardiovascular-related pathological conditions including hyperlipidemia and related cardiovascular pathologies, and estrogen-dependent cancer.
Type:
Grant
Filed:
September 19, 1997
Date of Patent:
January 5, 1999
Assignee:
Eli Lilly and Company
Inventors:
Michael Gregory Bell, Brian Stephen Muehl, Mark Alan Winter
Abstract: The invention provides benzothiophene compounds, of formula I, ##STR1## wherein R1, R2, R3, R4 and n are as defined in the specification, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions, including hyperlipidemia, and other cardiovascular pathologies.
Type:
Grant
Filed:
September 19, 1997
Date of Patent:
December 1, 1998
Assignee:
Eli Lilly and Company
Inventors:
Kenneth Lee Hauser, Alan David Palkowitz, Kenneth Jeff Thrasher
Abstract: The invention provides benzothiophene compounds, formulations, and methods of inhibiting bone loss or bone resorption, particularly osteoporosis, and cardiovascular-related pathological conditions including hyperlipidemia, and estrogen-dependent cancer.
Type:
Grant
Filed:
October 23, 1997
Date of Patent:
December 1, 1998
Assignee:
Eli Lilly and Company
Inventors:
George Joseph Cullinan, Brian Stephen Muehl
Abstract: The present invention provides novel methods of lowering serum cholesterol and inhibiting smoother muscle cell proliferation, particularly restenosis, in humans, and inhibiting uterine fibroid disease and endometriosis in women comprising administering to a human/woman in need of treatment an effective amount of a compound of formula I ##STR1## wherein R is C.sub.1 -C.sub.6 alkyl, C.sub.1 -C.sub.6 alkoxy, halo, or trifluoromethyl;R.sup.1 and R.sup.2 each are the same or different C.sub.1 -C.sub.6 alkyl group;n is an integer from 2 to 6; andR.sup.3 and R.sup.4 each are independently C.sub.1 -C.sub.4 alkyl, or combine to form a substituent selected from the group consisting of pyrrolidino, morpholino, piperidino, piperazino, 4-(C.sub.1 -C.sub.6 alkyl)piperazino, and 4-phenyl-piperazino; or a pharmaceutically acceptable salt thereof.
Abstract: The instant invention provides novel benzo?b!thiophene compounds, intermediates, compositions, pharmaceutical formulations, and methods of use for the inhibition of bone loss or bone resorption and for treatment of cardiovascular-related pathological conditions.